Using coverage information to predict the cost-effectiveness of regression testing strategies

1997 ◽  
Vol 23 (3) ◽  
pp. 146-156 ◽  
Author(s):  
D.S. Rosenblum ◽  
E.J. Weyuker
Keyword(s):  
Cost Effectiveness ◽  
Regression Testing ◽  
Testing Strategies ◽  
The Cost

The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori

2000 ◽  
Vol 95 (7) ◽  
pp. 1691-1698 ◽  
Author(s):  
Nimish Vakil ◽  
David Rhew ◽  
Andrew Soll ◽  
Joshua J. Ofman
Keyword(s):  
Helicobacter Pylori ◽  
Cost Effectiveness ◽  
Diagnostic Testing ◽  
Testing Strategies ◽  
The Cost

scholarly journals The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India

2019 ◽  
Vol 70 (4) ◽  
pp. 633-642 ◽  
Author(s):  
Pooyan Kazemian ◽  
Sydney Costantini ◽  
Nagalingeswaran Kumarasamy ◽  
A David Paltiel ◽  
Kenneth H Mayer ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Hiv Testing ◽  
Scale Up ◽  
Cost Effective ◽  
Status Quo ◽  
Hiv Incidence ◽  
Testing Strategies ◽  
Preexposure Prophylaxis ◽  
Immunodeficiency Virus ◽  
The Cost

Abstract Background The human immunodeficiency virus (HIV) epidemic in India is concentrated among 3.1 million men who have sex with men (MSM) and 1.1 million people who inject drugs (PWID), with a mean incidence of 0.9–1.4 per 100 person-years. We examined the cost-effectiveness of both preexposure prophylaxis (PrEP) and HIV testing strategies for MSM and PWID in India. Methods We populated an HIV microsimulation model with India-specific data and projected clinical and economic outcomes of 7 strategies for MSM/PWID, including status quo; a 1-time HIV test; routine HIV testing every 3, 6, or 12 months; and PrEP with HIV testing every 3 or 6 months. We used a willingness-to-pay threshold of US$1950, the 2017 Indian per capita gross domestic product, to define cost-effectiveness. Results HIV testing alone increased life expectancy by 0.07–0.30 years in MSM; PrEP added approximately 0.90 life-years to status quo. Results were similar in PWID. PrEP with 6-month testing was cost-effective for both MSM (incremental cost-effectiveness ratio [ICER], $1000/year of life saved [YLS]) and PWID (ICER, $500/YLS). Results were most sensitive to HIV incidence. PrEP with 6-month testing would increase HIV-related expenditures by US$708 million (MSM) and US$218 million (PWID) over 5 years compared to status quo. Conclusions While the World Health Organization recommends PrEP with quarterly HIV testing, our analysis identifies PrEP with semiannual testing as the cost-effective HIV prevention strategy for Indian MSM and PWID. Since nationwide scale-up would require a substantial fiscal investment, areas of highest HIV incidence may be the appropriate initial targets for PrEP scale-up.

Understanding the effects of changes on the cost-effectiveness of regression testing techniques

2003 ◽  
Vol 13 (2) ◽  
pp. 65-83 ◽  
Author(s):  
Sebastian Elbaum ◽  
Praveen Kallakuri ◽  
Alexey Malishevsky ◽  
Gregg Rothermel ◽  
Satya Kanduri
Keyword(s):  
Cost Effectiveness ◽  
Regression Testing ◽  
Testing Techniques ◽  
The Cost

scholarly journals The cost and cost-effectiveness of rapid testing strategies for yaws diagnosis and surveillance

2017 ◽  
Vol 11 (10) ◽  
pp. e0005985 ◽  
Author(s):  
Christopher Fitzpatrick ◽  
Kingsley Asiedu ◽  
Anita Sands ◽  
Tita Gonzalez Pena ◽  
Michael Marks ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Rapid Testing ◽  
Testing Strategies ◽  
The Cost
Sign in / Sign up

Export Citation Format

Share Document